Cantor Fitzgerald reiterated their overweight rating on shares of Mainz Biomed (NASDAQ:MYNZ – Free Report) in a report issued on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $9.00 target price on the stock. Separately, HC Wainwright boosted their price target on shares of Mainz Biomed from $7.00 to $9.00 and gave the stock […]